An investigation for investors in GenVec Inc (NASDAQ:GNVC) over potential securities laws violations by GenVec in connection certain financial statements was announced.
Investors who purchased shares of GenVec Inc (NASDAQ:GNVC), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether a series of statements by GenVec regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On January 8, 2016, Novartis notified GenVec, a biopharmaceutical company, that it would be pausing enrollment for the CGF166 clinical trial to conduct a safety review of patient data, based on the recommendation of the trial’s data safety monitoring board. The trial will continue to collect new safety and efficacy data on patients currently enrolled in the study.
Shares of GenVec Inc (NASDAQ:GNVC) closed as low as $0.46 per share on January 19, 2016.
Those who purchased shares of GenVec Inc (NASDAQ:GNVC) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
Leave Your Comments